Double-Digit-Growing Cancer Therapeutics Market Could Top $89 Billion by 2011!

February 18, 2007 (PRLEAP.COM) Health News
New York, February 18, 2007 — Expecting more than $11 billion in new therapeutics to gain approval within the next four years, the global market for cancer therapies is poised to surpass $89 billion in sales by 2011, according to Cancer Therapeutics: The Worldwide Market, the latest findings from market research firm Kalorama Information.

Forecast to display steady growth of more than 14% from 2006 to 2011, the market reached sales in excess of $46 billion in 2006, increasing by more than 18% over 2004 sales. Led by strong performance in the immunotherapy segment, which currently commands a slightly more than 31% market share, the market is also being bolstered by the radiation therapy segment as well as by product growth in several areas of the adjunctive therapies segment.

Innovation has been and will continue to be the key to growth. In 2006, 26 cancer therapies were approved in the U.S., the largest number in history. With more than 50 therapies currently in Phase III or awaiting approval, the cancer therapeutics is clearly the forerunner in drug development.

“Targeted cancer therapeutics are an exciting prospect that has the potential to improve patient survival from serious malignancies. Similarly, the prospect of combining new agents with older forms of therapy, such as small molecule chemotherapy or hormonal therapy, also offers promise for improvement in disease outcomes,” notes Melissa Elder, the report’s author. “At the same time, the incorporation of molecular tools into contemporary drug development is mandatory if the clinical impact of new anticancer agents is to be realized.”

This study examines the global market for therapies for a broad range of cancers including: bladder, breast, cervical, colorectal, kidney, leukemia, liver, lung, lymphoma, melanoma, multiple myeloma, ovarian, and prostate among others. Therapy types covered in the report include chemotherapy, hormone and radiation therapy, immunotherapy and biotherapy, and adjunctive therapies.

Cancer Therapeutics also includes extensive coverage of research and development pipelines, in-depth company profiles, four-region geographic breakdowns, over 160 tables and figures, and more. It can be purchased directly from Kalorama Information by visiting It is also available at

About Kalorama Information
Kalorama Information, a division of, supplies the latest in independent research for medical markets. For more information, contact Tom Ehart at 240-747-3014 or, or visit